drugset / Trial / NCT01602029
Randomized Double Blind Placebo Control Study in Patients with Schizophrenia
Phase 2
Completed
303 enrolled
Pakistan Institute of Living and Learning
Abbasi Shaheed Hospital · collabDow University of Health Sciences · collabStanley Medical Research Institute · collab
RandomizedFactorialDouble-blindTreatment
Summary
Negative symptoms and cognitive deficits are two partially-related features of schizophrenia which have a major negative impact on social function and objective quality of life. Standard drug treatments have little impact on either and arguably no effect on primary negative symptoms. Social dysfunction has major economic consequences in both the developed and developing world. There is evidence that anti-inflammatory treatment may have beneficial effects in patients with schizophrenia.
Timeline
- Start
- 2010-08
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ondansetron | Other / unclassified | 8 mg | — |
| Comparator | Simvastatin | Small molecule | 40 mg | — |